Efficacy and safety of burosumab in children aged 1–4 years with X-linked hypophosphataemia: a multicentre, open-label, phase 2 trial
Michael P. Whyte(Shriners Hospitals for Children - St. Louis), Erik A. Imel(Indiana University – Purdue University Indianapolis), Alison Skrinar, Thomas O. Carpenter(Yale University), Gary S. Gottesman(Shriners Hospitals for Children - St. Louis), Javier San Martín(Universidad Nacional de Educación a Distancia), Meng Mao(Guiyang Medical University)
Cited by 184
Related Papers
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
|New England Journal of Medicine|2009|3.5k
A Lancet Commission on 70 years of women's reproductive, maternal, newborn, child, and adolescent health in China
|The Lancet|2021|579
SLC34A3 Mutations in Patients with Hereditary Hypophosphatemic Rickets with Hypercalciuria Predict a Key Role for the Sodium-Phosphate Cotransporter NaPi-IIc in Maintaining Phosphate Homeostasis
|The American Journal of Human Genetics|2006|493
Burosumab Therapy in Children with X-Linked Hypophosphatemia
|New England Journal of Medicine|2018|479